Allarity Therapeutics, Inc.

Develops personalized cancer drugs using a diagnostic platform to predict patient response.

ALLR | US

Overview

Corporate Details

ISIN(s):: US0167445008
LEI:
Country:: United States of America
Address:: 24 SCHOOL ST., 2ND FLOOR, 2108 BOSTON
Website:: https://allarity.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Allarity Therapeutics, Inc. is a clinical-stage precision medicine company focused on developing personalized cancer treatments. The company leverages its proprietary Drug Response Predictor (DRP®) technology, a diagnostic platform that analyzes tumor biology to predict a patient's response to specific therapies. This approach aims to refine patient selection and improve clinical outcomes for its pipeline of in-licensed oncology therapeutics. Allarity's lead clinical program is stenoparib, an orally available, dual-action small molecule inhibitor being advanced for patients with advanced recurrent ovarian cancer. The company's mission is to enhance patient outcomes through data-driven decision-making and personalized cancer care.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Allarity Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Allarity Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Allarity Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Inhibikase Therapeutics, Inc. Develops kinase inhibitors to treat neurodegenerative diseases like Parkinson's.	United States of America	IKT
Inhibrx Biosciences, Inc. Clinical-stage biopharma developing novel biologic therapies for life-threatening cancers.	United States of America	INBX
InMed Pharmaceuticals Inc. Develops cannabinoid drugs for unmet medical needs and supplies rare cannabinoids for B2B wellness.	United States of America	INM
Inmune Bio, Inc. Develops immunotherapies reprogramming innate immunity for cancer, Alzheimer's, and inflammation.	United States of America	INMB
Innate Pharma SA Developing first-in-class antibody immunotherapies for cancer via the innate immune system.	United States of America	IPHA
INOVIO PHARMACEUTICALS, INC. Develops DNA medicines delivered via smart devices for cancer, HPV, and infectious diseases.	United States of America	INO
Insight Molecular Diagnostics Inc. Develops molecular diagnostic tests for oncology and transplant monitoring for clinicians & researchers.	United States of America	IMDX
INSMED Inc Develops and commercializes innovative therapies for serious and rare diseases.	United States of America	INSM
Instil Bio, Inc. Developing autologous TIL cell therapies using a patient's own immune cells to fight solid tumors.	United States of America	TIL
Intellia Therapeutics, Inc. Developing curative CRISPR/Cas9 genome editing therapies for severe genetic disorders.	United States of America	NTLA